Long-term natalizumab treatment enhances the pathogenic signature of Th17 cells - potential implications for treatment cessation?

Janoschka C, Schulte-Mecklenbeck A, Starost L, Schafflick D, Schneider-Hohendorf T, Hoerste GM, Gross CC, Schwab N, Kuhlmann T, Wiendl H, Klotz L